| Identification | Back Directory | [Name]
(+/-)-(5ALPHA,7ALPHA,8BETA)-3,4-DICHLORO-N-METHYL-N-(7-[1-PYRROLIDINYL]-1-OXASPIRO[4.5]DEC-8-YL)BENZENEACETAMIDE MESYLATE | [CAS]
87173-97-5 | [Synonyms]
U-62066
U-62066 (mesylate)
SPIRADOLINE MESYLATE
rel-3,4-dichloro-N-methyl-N-[(5S,7R,8R)-7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide,monomethanesulfonate
(+/-)-(5ALPHA,7ALPHA,8BETA)-3,4-DICHLORO-N-METHYL-N-(7-[1-PYRROLIDINYL]-1-OXASPIRO[4.5]DEC-8-YL)BENZENEACETAMIDE MESYLATE | [Molecular Formula]
C23H34Cl2N2O5S | [MDL Number]
MFCD00153876 | [MOL File]
87173-97-5.mol | [Molecular Weight]
521.49 |
| Hazard Information | Back Directory | [Uses]
Analgesic. | [in vivo]
Spiradoline mesylate (U-62066; 0.1-0.4 mg/kg; subcutaneous injection; once; Sprague-Dawley rats) treatment dose-dependently reduces social behaviors in non-stressed adults, producing social avoidance at the highest dose tested, while younger animals displays reduced sensitivity to this socially suppressing effect of Spiradoline mesylate. In stressed animals, the socially suppressing effects of the Spiradoline mesylate are blunted at all ages, with juveniles and adolescents exhibiting increased social preference in response to certain doses of U-62066[1]. | Animal Model: | Juvenile, adolescent and adult Sprague-Dawley male and female rats exposured to repeated restraint[1] | | Dosage: | 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, and 0.4?mg/kg | | Administration: | Subcutaneous injection; once | | Result: | Dose-dependently reduced social behaviors in non-stressed adults, producing social avoidance at the highest dose tested. |
|
|